2,3,7,8-tetrachlorodibenzo-p-dioxin induced Cell-Specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells

Journal of Korean Medical Science

Volumn 29, Issue 9, 2014, Pages 1188-1198

  Gotovdorj, Tuvshinjargal ^a,b   Lee, Eunil ^a,b   Lim, Yongchul ^b   Cha, Eun Jeong ^b   Kwon, Daeho ^c   Hong, Eunyoung ^a   Kim, YunJeong ^a   Oh, Min Yeong ^a  

^a Korea University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Catholic Kwandong University   (South Korea)

Author keywords

ABCG2; Acquired cisplatin resistance; AhR; Drug transporters; TCDD

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ABC TRANSPORTER; ABCC5 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; AROMATIC HYDROCARBON RECEPTOR; CISPLATIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; KAEMPFEROL; KAEMPFEROL DERIVATIVE; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; RIBONUCLEOPROTEIN; SLC29A2 PROTEIN, HUMAN; TUMOR PROTEIN;

CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; JURKAT CELL LINE; K562 CELL LINE; METABOLISM; TUMOR CELL LINE; UPREGULATION;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; HUMANS; JURKAT CELLS; K562 CELLS; KAEMPFEROLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; TETRACHLORODIBENZODIOXIN; UP-REGULATION; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 84929669274     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.9.1188     Document Type: Article

References (40)

1. Schecter A, Birnbaum L, Ryan JJ, Constable JD. Dioxins: an overview. Environ Res 2006; 101: 419-28.
2. Pohjanvirta R, Tuomisto J. Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals: effects, mechanisms, and animal models. Pharmacol Rev 1994; 46: 483-549.
3. Poland A, Knutson JC. 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol 1982; 22: 517-54.
4. McGuire J, Coumailleau P, Whitelaw ML, Gustafsson JA, Poellinger L. The basic helix-loop-helix/PAS factor Sim is associated with hsp90: implications for regulation by interaction with partner factors. J Biol Chem 1995; 270: 31353-7.
5. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005; 28: 249-68.
6. Hagenbuch B. Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol Ther 2010; 87: 39-47.
7. Xu S, Weerachayaphorn J, Cai SY, Soroka CJ, Boyer JL. Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am J Physiol Gastrointest Liver Physiol 2010; 299: G126-35.
8. Wang X, Hawkins BT, Miller DS. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 2011; 25: 644-52.
9. Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 2005; 33: 956-62.
10. Lee JH, Lee EI, Kwon DH, Lim YC, Oh SN, Oh MY, Hong EY. Upregulation of cancer-related genes in HepG2 cells by TCDD requires PRMT I and IV. Mol Cell Toxicol 2010; 6: 111-8.
11. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. ABCG2: a perspective. Adv Drug Deliv Rev 2009; 61: 3-13.
12. Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 2012; 3: 1-27.
13. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79.
14. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 2006; 234: 34-9.
15. Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005; 53: 13-23.
16. Liu JJ, Lu J, McKeage MJ. Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Curr Cancer Drug Targets 2012; 12: 962-86.
17. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 2011; 14: 22-34.
18. Tan KP, Wang B, Yang M, Boutros PC, Macaulay J, Xu H, Chuang AI, Kosuge K, Yamamoto M, Takahashi S, et al. Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). Mol Pharmacol 2010; 78: 175-85.
19. Tompkins LM, Li H, Li L, Lynch C, Xie Y, Nakanishi T, Ross DD, Wang H. A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol 2010; 80: 1754-61.
20. To KK, Yu L, Liu S, Fu J, Cho CH. Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. Mol Carcinog 2012; 51: 449-64.
21. Ekblad L, Kjellström J, Johnsson A. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Anticancer Drugs 2010; 21: 523-31.
22. Lee TB, Choi CH. Detection of drug transporter expression using a 25-multiplex RT-PCR assay. Biotechnol Lett 2009; 31: 1485-92.
23. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 2010; 159: 898-908.
24. Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, Romero IA, Scherrmann JM, De Waziers I, Declèves X. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 2009; 77: 897-909.
25. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006; 34: 1756-63.
26. Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T, Yokoyama T. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol 2008; 62: 577-84.
27. Griffiths M, Yao SY, Abidi F, Phillips SE, Cass CE, Young JD, Baldwin SA. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 1997; 328: 739-43.
28. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schönfeld C, Löffler M, Reyes G, Duszenko M, Karhausen J, et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 2005; 202: 1493-505.
29. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000; 247: 521-34.
30. Chen HH, Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010; 2010. pii: 430939.
31. To KK, Robey R, Zhan Z, Bangiolo L, Bates SE. Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway. Mol Cancer Res 2011; 9: 516-27.
32. Peng TL, Chen J, Mao W, Liu X, Tao Y, Chen LZ, Chen MH. Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer. World J Gastroenterol 2009; 15: 1719-29.
33. Dolwick KM, Schmidt JV, Carver LA, Swanson HI, Bradfield CA. Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol 1993; 44: 911-7.
34. Harper PA, Prokipcak RD, Bush LE, Golas CL, Okey AB. Detection and characterization of the Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in the human colon adenocarcinoma cell line LS180. Arch Biochem Biophys 1991; 290: 27-36.
35. Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S, Zhang L, Han Z. Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer 2010; 126: 841-51.
36. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004; 279: 24218-25.
37. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem 2010; 285: 31100-6.
38. Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y, He Z. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 2011; 43: 647-53.
39. Shimamoto Y, Sumizawa T, Haraguchi M, Gotanda T, Jueng HC, Furukawa T, Sakata R, Akiyama S. Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol Rep 2006; 15: 645-52.
40. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-6.